S&P 500   3,148.56 (+1.00%)
DOW   28,007.93 (+1.19%)
QQQ   204.94 (+1.24%)
AAPL   270.20 (+1.74%)
FB   200.87 (+0.76%)
MSFT   151.34 (+0.94%)
GOOGL   1,339.09 (+1.53%)
AMZN   1,748.40 (-0.70%)
CGC   18.60 (+0.00%)
NVDA   212.42 (+1.43%)
MU   48.04 (+3.02%)
BABA   201.66 (+0.83%)
GE   11.00 (+1.95%)
AMD   39.79 (+0.25%)
ACB   2.43 (-0.41%)
F   9.04 (+1.23%)
PRI   136.08 (+1.33%)
BAC   33.76 (+2.02%)
S&P 500   3,148.56 (+1.00%)
DOW   28,007.93 (+1.19%)
QQQ   204.94 (+1.24%)
AAPL   270.20 (+1.74%)
FB   200.87 (+0.76%)
MSFT   151.34 (+0.94%)
GOOGL   1,339.09 (+1.53%)
AMZN   1,748.40 (-0.70%)
CGC   18.60 (+0.00%)
NVDA   212.42 (+1.43%)
MU   48.04 (+3.02%)
BABA   201.66 (+0.83%)
GE   11.00 (+1.95%)
AMD   39.79 (+0.25%)
ACB   2.43 (-0.41%)
F   9.04 (+1.23%)
PRI   136.08 (+1.33%)
BAC   33.76 (+2.02%)
S&P 500   3,148.56 (+1.00%)
DOW   28,007.93 (+1.19%)
QQQ   204.94 (+1.24%)
AAPL   270.20 (+1.74%)
FB   200.87 (+0.76%)
MSFT   151.34 (+0.94%)
GOOGL   1,339.09 (+1.53%)
AMZN   1,748.40 (-0.70%)
CGC   18.60 (+0.00%)
NVDA   212.42 (+1.43%)
MU   48.04 (+3.02%)
BABA   201.66 (+0.83%)
GE   11.00 (+1.95%)
AMD   39.79 (+0.25%)
ACB   2.43 (-0.41%)
F   9.04 (+1.23%)
PRI   136.08 (+1.33%)
BAC   33.76 (+2.02%)
S&P 500   3,148.56 (+1.00%)
DOW   28,007.93 (+1.19%)
QQQ   204.94 (+1.24%)
AAPL   270.20 (+1.74%)
FB   200.87 (+0.76%)
MSFT   151.34 (+0.94%)
GOOGL   1,339.09 (+1.53%)
AMZN   1,748.40 (-0.70%)
CGC   18.60 (+0.00%)
NVDA   212.42 (+1.43%)
MU   48.04 (+3.02%)
BABA   201.66 (+0.83%)
GE   11.00 (+1.95%)
AMD   39.79 (+0.25%)
ACB   2.43 (-0.41%)
F   9.04 (+1.23%)
PRI   136.08 (+1.33%)
BAC   33.76 (+2.02%)
Log in

NASDAQ:GRTX - Galera Therapeutics Stock Price, Forecast & News

$10.66
-0.24 (-2.20 %)
(As of 12/6/2019 01:55 PM ET)
Today's Range
$10.54
Now: $10.66
$10.89
50-Day Range N/A
52-Week Range
$11.50
Now: $10.66
$14.88
Volume2,217 shs
Average Volume108,557 shs
Market Capitalization$259.68 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Galera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis. It is also involved in developing GC4711, which is in Phase I clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is based in Malvern, Pennsylvania.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRTX
CUSIPN/A
CIKN/A
Phone610-725-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees26
Market Cap$259.68 million
Next Earnings DateN/A
OptionableNot Optionable

Receive GRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.


Galera Therapeutics (NASDAQ:GRTX) Frequently Asked Questions

What is Galera Therapeutics' stock symbol?

Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX."

What price target have analysts set for GRTX?

4 analysts have issued 1 year target prices for Galera Therapeutics' stock. Their forecasts range from $14.00 to $30.00. On average, they expect Galera Therapeutics' stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 87.4% from the stock's current price. View Analyst Price Targets for Galera Therapeutics.

What is the consensus analysts' recommendation for Galera Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galera Therapeutics.

Has Galera Therapeutics been receiving favorable news coverage?

News coverage about GRTX stock has trended neutral this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Galera Therapeutics earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Galera Therapeutics.

Who are some of Galera Therapeutics' key competitors?

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Alibaba Group (BABA), Honeywell International (HON), Thermo Fisher Scientific (TMO), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Verizon Communications (VZ), Amgen (AMGN), Cisco Systems (CSCO) and Johnson & Johnson (JNJ).

Who are Galera Therapeutics' key executives?

Galera Therapeutics' management team includes the folowing people:
  • Dr. J. Mel Sorensen, CEO, Pres & Director (Age 62)
  • Dr. Robert A. Beardsley, Co-Founder, COO & Sec. (Age 58)
  • Mr. Christopher Degnan, Chief Financial Officer (Age 40)
  • Mr. Joel F. Sussman, Chief Accounting Officer (Age 70)
  • Dr. Dennis P. Riley Ph.D., Chief Scientific Officer

When did Galera Therapeutics IPO?

(GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

When does Galera Therapeutics' quiet period expire?

Galera Therapeutics' quiet period expires on Tuesday, December 17th. Galera Therapeutics had issued 5,000,000 shares in its IPO on November 7th. The total size of the offering was $60,000,000 based on an initial share price of $12.00. During Galera Therapeutics' quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Galera Therapeutics?

Shares of GRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galera Therapeutics' stock price today?

One share of GRTX stock can currently be purchased for approximately $10.54.

How big of a company is Galera Therapeutics?

Galera Therapeutics has a market capitalization of $256.75 million. Galera Therapeutics employs 26 workers across the globe.View Additional Information About Galera Therapeutics.

What is Galera Therapeutics' official website?

The official website for Galera Therapeutics is http://www.galeratx.com/.

How can I contact Galera Therapeutics?

Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 110, MALVERN PA, 19355. The company can be reached via phone at 610-725-1500.


MarketBeat Community Rating for Galera Therapeutics (NASDAQ GRTX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  20
MarketBeat's community ratings are surveys of what our community members think about Galera Therapeutics and other stocks. Vote "Outperform" if you believe GRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel